Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Koh, Yi T ^a   Higgins, Sean A ^a   Weber, Jeffrey S ^a   Kast, W Martin ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; PROTEIN E7; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG STABILITY; EMBRYO; EMULSION; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL TECHNIQUE; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; TUMOR; TUMOR REJECTION;

EID: 33750719986     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-42     Document Type: Article

References (33)

1. Moignic L, Pinoy: Les vaccins en emulsion dans les corps gras ou 'lipo-vaccins'. Comptes Rendus de la Societe de Biologie 1916, 79:201-203.
2. Freund J, Casals J, Hosmer EP: Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med 1937, 37:509-513.
3. Freund J: The mode of action of immunologic adjuvants. Biol Tuberc 1956:130-148.
4. Behar AJ, Tal C: Experimental liver necrosis produced by the injection of homologous whole liver with adjuvant. J Pathol Bacteriol 1959, 77:591-596.
5. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL: Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med 1959, 100:660-664.
6. Steiner JW, Langer B, Schatz DL: The local and systemic effects of Freund's adjuvant and its fractions. Arch Pathol 1960, 70:424-434.
7. Edelman R: Vaccine adjuvants. Rev Infect Dis 1980, 2:370-383.
8. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK: Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993, 11:293-306.
9. Jensen FC, Savary JR, Diveley JP, Chang JC: Adjuvant activity of incomplete Freund's adjuvant. Adv Drug Deliv Rev 1998, 32:173-186.
10. Stills HF Jr.: Adjuvants and antibody production: dispelling the myths associated with Freund's complete, and other adjuvants. Ilar J 2005, 46:280-293.
11. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Garine V: Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002, 1:111-118.
12. Aucouturier J, Dupuis L, Ganne V: Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672.
13. Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother 2006, 29:224-231.
14. Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H: Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 2005, 54:208-218.
15. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P: Rapid and strong human CD8+ T cell responses to vaccination with pepticle, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115:739-746.
16. Moncada C, Torres V, Israel Y: Simple method for the preparation of antigen emulsions for immunization. J Immunol Methods 1993, 162:133-140.
17. Weijzen S, Meredith SC, Velders MP, Elmishad AG, Schreiber H, Kast WM: Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J Immunol 2001, 166:7151-7157.
18. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H: Antigen localisation regulates immune responses in a close-and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997, 156:199-209.
19. Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H: T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995, 182:261-266.
20. Freund J: The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review. Am J Clin Pathol 1951, 21:645-656.
21. Osebold JW: Mechanisms of action by immunologic adjuvants. J Am Vet Med Assoc 1982, 181:983-987.
22. Page M, Thorpe R: Immunogen preparation and immunization procedures for rats and mice. The protein protocols handbook 2nd Ed.: 1109-1110.
23. Herbert WJ: Miineral-oil adjuvants and the immunization of laboratory animals. In Handbook of experimental Immunology Volume 3. Edited by: Weir DM. Oxford, Blackwell: 1973:A2.1-A2.14.
24. Flies DB, Chen L: A simple and rapid vortex method for preparing antigen/ adjuvant emulsions for immunization. J Immunol Methods 2003, 276:239-242.
25. Miles AP, McClellan HA, Rausch KM, Zhu D, Whitmore MD, Singh S, Martin LB, Wu Y, Giersing BK, Stowers AW, Long CA, Saul A: Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005, 23:2530-2539.
26. Leenaars M, Koedam MA, Hendriksen CF, Claassen E: Immune responses and side effects of five different oil-based adjuvants in mice. Vet Immunol Immunopathol 1998, 61:291-304.
27. Chidambaram N, Burgess DJ: Emulsions: Design and Manufacturing. In Injectable dispersed systems: Formulation, processing and performance Edited by: Burgess DJ. Boca Raton, Taylor and Francis group; 2005:213-248.
28. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP: Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003, 97:186-200.
29. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23:2242-2249.
30. Muderhwa JM, Matyas GR, Spitler LE, Alving CR: Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J Pharm Sci 1999, 88:1332-1339.
31. Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG: Progression of Armed CTL from Draining Lymph Node to Spleen Shortly After Localized Infection with Herpes Simplex Virus I. J Immunol 2002, 168:834-838.
32. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, Kast WM: Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006, 24:5235-5244.
33. Scott RR, Tabibi SE: A practival guide to equipment selection and operating techniques. In Pharmaceutical dosage forms: Disperse systems Volume 3. Edited by: Lieberman HA, Rieger MM and Banker GS. New York. Marcel Dekker, Inc.; 1998:291-362.